

PHARMACY PRE-AUTHORIZATION CRITERIA



DRUG	Rexulti (brexipiprazole)
POLICY #	11137
INDICATIONS	Rexulti is indicated for: <ol style="list-style-type: none">1. The treatment of schizophrenia2. The adjunctive treatment to antidepressants for the treatment of major depressive disorder (MDD)
CRITERIA	<p><u>Criteria for the diagnosis of Major Depressive Disorder:</u></p> <p>Rexulti is covered for depression and related conditions only if there is:</p> <ol style="list-style-type: none">1) Failure or intolerance to at least two (2) first line agents listed below AND2) Concurrent use of an antidepressant AND3) Failure of Abilify when tried in combination with an antidepressant OR4) Patient has taken Rexulti at any time in the past with success and discontinued use. They may then receive authorization to restart. <p><u>First-line agents:</u></p> <p>Any of the 6 SSRI's: citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, escitalopram</p> <p>Any of the 6 SNRI's: Cymbalta, Pristiq, venlafaxine ER, Desvenlafaxine Fumarate, Fetzima, Khedezla</p> <p>Other antidepressants: Viibryd, bupropion, Trintellix</p> <p><u>Criteria for the diagnosis of Schizophrenia:</u></p> <p>Rexulti is covered for the treatment of Schizophrenia when the following criteria is met:</p> <ol style="list-style-type: none">1) Clinical diagnosis made by a psychiatrist AND2) Failure or intolerance to any one of the 6 generic atypical antipsychotics: aripiprazole, quetiapine, ziprasidone, risperidone, olanzapine or clozapine OR3) Patient has taken Rexulti at any time in the past with success and discontinued use. They may then receive authorization to restart.

PHARMACY PRE-AUTHORIZATION CRITERIA

DRUG	Rexulti (brexipiprazole)
LIMITATIONS	<ul style="list-style-type: none"> • If the above criteria are met initial authorization will be given for 1 year • A current progress note must be submitted for reauthorization
REFERENCES	<ol style="list-style-type: none"> 1. Facts & Comparisons online 2. Rexulti package insert, Otsuka Pharmaceuticals, Tokyo, Japan
P&T REVIEW HISTORY	11/15, 5/16, 2/17, 1/18
REVISION RECORD	2/16